Unnoticed Adverse Effect of Isoniazid during Childhood Tuberculosis Preventive Treatment: Hyperuricemia

Basit Öğe Kaydı
dc.contributor.authorKandemir, Bahar
dc.contributor.authorDuman, Ipek
dc.contributor.authorDurduran, Yasemin
dc.contributor.authorMetin Akcan, Ozge
dc.contributor.authorSelver, Muhammed Burak
dc.contributor.authorPekcan, Sevgi
dc.date.accessioned2024-02-23T14:16:59Z
dc.date.available2024-02-23T14:16:59Z
dc.date.issued2021
dc.departmentNEÜen_US
dc.description.abstractObjective Isoniazid for 6 to 9 months is the most widely used form of tuberculosis (TB) preventive treatment. We aimed to assess the adverse effects of isoniazid by using the serum levels of aspartate transaminase (AST), alanine transaminase (ALT), and uric acid (SUA) in children and adolescents receiving long-term isoniazid for latent TB infection. Methods The study included children <= 18 years of age who underwent TB preventive treatment with isoniazid (IPT) between 2015 and 2019 at a university hospital. Serum transaminase, SUA, urea, and creatinine levels of patients were measured before the initiation of IPT, 15th day, and once a month during treatment. Patients with ALT, AST, or SUA results above cut-off levels during treatment were evaluated. The final values in follow-up were included in the data analysis. Results A total of 141 children who underwent IPT were included. In total, 70 children had family members with confirmed TB disease, and 71 children had a positive tuberculin skin test. SUA increased above cut-off values in 16 children (11.3%), and half of them had uric acid levels over 7 mg/dL. The median duration of the development of hyperuricemia was 4.0 months. ALT or AST increased above cut-off values in 23 children (16.3%). ALT was above cut-off values in seven patients, AST was high in 20 patients. The median duration to the development of AST and/or ALT levels above cut-off was 4.0 months. Two patients had hepatotoxic transaminase levels. Three patients had both elevated transaminases and SUA levels. Conclusion Isoniazid may also cause hyperuricemia besides elevation in transaminases in children.en_US
dc.identifier.doi10.1055/s-0041-1724022
dc.identifier.endpage121en_US
dc.identifier.issn1305-7707
dc.identifier.issn1305-7693
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-85102620940en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage116en_US
dc.identifier.urihttps://doi.org/10.1055/s-0041-1724022
dc.identifier.urihttps://hdl.handle.net/20.500.12452/12874
dc.identifier.volume16en_US
dc.identifier.wosWOS:000627561000001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherGeorg Thieme Verlag Kgen_US
dc.relation.ispartofJournal Of Pediatric Infectious Diseasesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectIsoniaziden_US
dc.subjectPreventionen_US
dc.subjectTransaminaseen_US
dc.subjectTuberculosisen_US
dc.subjectUric Aciden_US
dc.titleUnnoticed Adverse Effect of Isoniazid during Childhood Tuberculosis Preventive Treatment: Hyperuricemiaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu